137 related articles for article (PubMed ID: 10851966)
1. Drug recalls underscore safety concerns.
Greene HL
Health News; 2000 May; 6(5):4. PubMed ID: 10851966
[No Abstract] [Full Text] [Related]
2. Plaintiff's attorney actively seeking out patients who have used various FDA approved medications and who "may be entitled to compensation for damages caused by these medications".
South D
J Miss State Med Assoc; 2000 Nov; 41(11):798-9. PubMed ID: 11107716
[No Abstract] [Full Text] [Related]
3. The chase is on (and I'm mad as hell).
Ponte CD
J Am Pharm Assoc (Wash); 2000; 40(4):466. PubMed ID: 10932454
[No Abstract] [Full Text] [Related]
4. Drugs and disease.
SoRelle R
Circulation; 2000 Apr; 101(13):E9027-8. PubMed ID: 10747361
[No Abstract] [Full Text] [Related]
5. From the Food and Drug Administration.
JAMA; 2000 May; 283(17):2228. PubMed ID: 10807369
[No Abstract] [Full Text] [Related]
6. Serious liver injury. Leading reason for drug removals, restrictions.
Meadows M
FDA Consum; 2001; 35(3):8-9. PubMed ID: 11458559
[No Abstract] [Full Text] [Related]
7. The FDA: protector or puppet?
Terpening CM
Pharmacotherapy; 2000 Jul; 20(7):860-1. PubMed ID: 10907979
[No Abstract] [Full Text] [Related]
8. Advisory panel hears contradictory evidence, backs keeping troglitazone on market.
Miller JL
Am J Health Syst Pharm; 1999 May; 56(9):840, 842. PubMed ID: 10344603
[No Abstract] [Full Text] [Related]
9. Diabetes drug Rezulin: take it, but take precautions.
Health News; 1999 May; 5(6):7. PubMed ID: 10546576
[No Abstract] [Full Text] [Related]
10. Update in endocrinology.
Whitcomb RW
Ann Intern Med; 1998 May; 128(10):871. PubMed ID: 9599203
[No Abstract] [Full Text] [Related]
11. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL
Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596
[TBL] [Abstract][Full Text] [Related]
12. New safety recommendations for use of cisapride (Propulsid).
Harv Heart Lett; 2000 Apr; 10(8):7. PubMed ID: 10712753
[No Abstract] [Full Text] [Related]
13. Diabetes medicine update. Old dogs, new tricks.
Nakamoto M
Diabetes Self Manag; 2003; 20(1):14-5. PubMed ID: 12632553
[No Abstract] [Full Text] [Related]
14. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Gorman C
Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
[No Abstract] [Full Text] [Related]
15. Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Diabetes Technol Ther; 2000; 2(2):292. PubMed ID: 11469275
[No Abstract] [Full Text] [Related]
16. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
[TBL] [Abstract][Full Text] [Related]
17. Warner-Lambert voluntarily withdraws Rezulin.
Diabetes Technol Ther; 2000; 2(2):290. PubMed ID: 11469273
[No Abstract] [Full Text] [Related]
18. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
[No Abstract] [Full Text] [Related]
19. FDA drug-review, surveillance processes under scrutiny.
Miller JL
Am J Health Syst Pharm; 1999 Mar; 56(5):404, 406, 408. PubMed ID: 10096696
[No Abstract] [Full Text] [Related]
20. Rezulin to be withdrawn from the market.
Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
